More Galleries
Rebirth of America's dead factories Defunct factories around the country are in high demand as U.S. production once again revs up. More
7 hot businesses to start now It's hard to predict what businesses will take off, but these startup ideas have been drawing tons of interest from entrepreneurs and their customers on More
How will a minimum wage hike hit businesses? Thirteen states increased the minimum wage on Jan. 1, and President Obama supports raising the federal rate to $10.10. 4 small business owners weigh in on how an increase would affect them. More

Special Offer
30 of 36
Stop the bleeding
Stop the bleeding
Bani Cipriano, Matthew Dowling and Peter Thomas
Team name: Remedium Technologies

School: University of Maryland, Robert H. Smith School of Business

Team Members: Matthew Dowling, Peter Thomas, Bani Cipriano, Oluwatosin Ogunsola, Akinola Dosunmu

Concept: Remedium Technologies is developing products designed to stop bleeding caused by injury or surgery. The company has two products in the works: a freeze-dried sponge, to be applied directly to a wound in order to control hemorrhaging; and a spray-on liquid to treat minor bleeding and seal tissue during surgical procedures.

Both products rely on a proprietary biopolymer-based material that gently adheres to tissue. The material comes off easily after the wound heals.

The sponge will be marketed to the U.S. military and hospital emergency rooms. The spray will be marketed to hospital surgical centers. Remedium believes its product is more effective than similar products currently on the market, and also cheaper to manufacture, giving the company a competitive edge.

Team members Dowling and Thomas are Ph.D. candidates studying bioengineering, with experience researching biopolymers. Ogunsola has a Ph.D. in chemical engineering and is a research associate at the U.S. Food and Drug Administration.

Timeline: The sponge and spray are currently undergoing pre-clinical testing on pigs, and the company has applied for a provisional patent for its biopolymer technology. The team estimates two years for product development and FDA approval. One year after the U.S. launch, the company plans to expand into Africa and South America, where inexpensive medical solutions are in demand, with help from government and philanthropic organizations. The company expects to be profitable by year three. -Stephenie Fletcher

NEXT: New help for diabetics

Last updated May 02 2008: 11:51 AM ET
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.